Etienne Fauquier serves as the Executive Director of Global Commercial Strategy and Team Lead for the Lymphoma Franchise at Kite Pharma, where he plays a pivotal role in shaping the future of CAR-T cell therapies. With a robust background in oncology and cell therapy, Etienne...
Etienne Fauquier serves as the Executive Director of Global Commercial Strategy and Team Lead for the Lymphoma Franchise at Kite Pharma, where he plays a pivotal role in shaping the future of CAR-T cell therapies. With a robust background in oncology and cell therapy, Etienne is at the forefront of advancing innovative treatments for hematologic malignancies, specifically through his leadership of the YESCARTA and TECARTUS brands. His expertise in market analysis and strategic marketing is instrumental in driving the global brand strategy and ensuring launch excellence for these groundbreaking therapies.
At Kite Pharma, Etienne leads a talented team of global marketing leaders, fostering a collaborative environment that emphasizes cross-functional teamwork. His responsibilities extend to overseeing the global commercial strategy for YESCARTA, a leading CAR-T therapy, and the emerging CD19/20 dual auto CAR-T programs. His strategic vision is complemented by his strong foundation in pharmaceuticals and biotechnology, enabling him to navigate the complexities of the market while delivering impactful solutions for patients.
Etienne’s leadership is characterized by his commitment to leveraging data-driven insights and market research to inform decision-making and optimize marketing budgets. His role also involves engaging with medical affairs and advisory boards to ensure that Kite Pharma remains at the cutting edge of innovation in the biotechnology sector. With a PharmD and an MBA focused on International Marketing from the University of Southern California, Etienne combines clinical knowledge with business acumen, positioning him as a key player in the ongoing evolution of CAR-T therapies and their application in treating lymphoma.
